Aerpio Therapeutics grabs $22 mln

Aerpio Therapeutics said Wednesday that it has raised $22 million in funding. OrbiMed led the round with participation from return backers Novartis Venture Funds, Satter Investment Management, Kearny Venture Partners, Venture Investors, Triathlon Medical Ventures and Athenian Venture Partners. In addition to the funding, OrbiMed’s Chau Q. Khuong has been added to Aerpio’s board of directors. Based in Cincinnati, Aerpio Therapeutics is a biopharmaceutical firm focused on therapies for vascular diseases.

VC-backed Akebia Therapeutics launches IPO

Akebia Therapeutics has launched its IPO of over 5.8 million shares at $17 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “AKBA.” Morgan Stanley, Credit Suisse and UBS Investment Bank are the lead underwriters. Based in Cincinnati, OH, Akebia Therapeutics is a biotech company focused on developing treatments for anemia and cancer. Its backers include Satter Investment Management, Novo A/S, Novartis Venture Funds, Kearny Venture Partners, Athenian Venture Partners and Triathlon Medical Ventures.

112 Views

VC-backed TriVascular files for IPO

TriVascular Technologies has filed for an IPO. The number of shares that will be offered as well as its pricing terms have yet to be set. The stock will trade on the NASDAQ under the ticker symbol “TRIV.” J.P. Morgan Securities and Credit Suisse Securities are the lead underwriters. Based in Santa Rosa, Calif., TriVascular Technologies is a provider of endovascular aortic repair solutions. Its backers include NEA, Delphi Ventures, MPM Capital, Kearny Venture Partners, Kaiser Permanente Ventures, Rock Springs Capital and Permal Asset Management.

ViewRay Raises Fresh $15M for Its Medical Imaging Technology

ViewRay Inc., a Cleveland-based medical device company, has raised $15 million in fresh funding, raising the total amount raised by the company to nearly $100 million. The company’s machinery, which can produce real-time images of cancerous tumors while the tumors are being treated radiation, raised what has been in its biggest round, a $45 million Series C, last year. ViewRay’s investors include Aisling Capital, Fidelity Biosciences, Kearny Venture Partners, OrbiMed Advisors and Siemens Venture Capital.

Phizer Buys VC-Backed NextWave Pharmaceuticals

Phizer is snapping up NextWave Pharmaceuticals—a company backed by a laundry list of investors including Panorama Capital, Bay City Capital, Kearny Venture Partners, Aisling Capital, Fidelity Biosciences, Sofinnova Ventures and Vivo Ventures. Under the terms of the deal, Pfizer will pay $255 million to NextWave’s shareholders at closing. NextWave’s shareholders are eligible to receive up to $425 million in additional money, based on sales milestones. NextWave closed a $45 million round last January.

AxioMed Closes Series D Financing

AxioMed Spine Corporation, a spinal orthopedics company has closed its Series D financing, raising $5 million in two tranches from current and new investors. This funding boosts the previously announced $15 million Series D financing. Investors in the business include Siemens Venture Capital, Aisling Capital, Fidelity Biosciences, Kearny Venture Partners and OrbiMed Advisors. PRESS RELEASE […]

Akebia Therapeutics Closes $4.1M in Series B

Akebia Therapeutics Inc., a pharmaceutical company focused on treatments for anemia, has drawn down a $4.1 million tranche of its previously announced Series B financing. Investors included Novartis Bioventures, Venture Investors, Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners, Sigvion Capital and AgeChem Venture Fund.

Akebia Therapeutics Inks $22M

Cincinnati-based Akebia Therapeutics has closed on $22 million in Series B financing. Existing shareholders Novartis Venture Fund and Venture Investors co-led the round, which also saw participation from Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners and Sigvion Capital and new investors including AgeChem Venture Fund. Akebia develops pharmaceuticals focused on anemia and vascular disorders. The $22 million Series B round includes a $14 million first closing. In addition, the company has the right to access another $8 million through the end of 2011.

AxioMed Spine Further Funded by Ohio Loan–CORRECTED

AxioMed Spine, which manufactures artificial disc replacements for medical patients, received $500,000 in the form of a loan from the state of Ohio to continue developing an artificial cervical spine disc. The company has raised $56 million to date from investors including Siemens Venture Capital GmbH, Aisling Capital, Fidelity Biosciences, Kearny Venture Partners and OrbiMed Advisors.

PEHUB Community

Join the 12500 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget